JP2024007504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024007504A5 JP2024007504A5 JP2023108177A JP2023108177A JP2024007504A5 JP 2024007504 A5 JP2024007504 A5 JP 2024007504A5 JP 2023108177 A JP2023108177 A JP 2023108177A JP 2023108177 A JP2023108177 A JP 2023108177A JP 2024007504 A5 JP2024007504 A5 JP 2024007504A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- acceptable salt
- therapeutic agent
- pharma
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 51
- 229940124597 therapeutic agent Drugs 0.000 claims 41
- 150000003839 salts Chemical class 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 25
- 102200006538 rs121913530 Human genes 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 231100000371 dose-limiting toxicity Toxicity 0.000 claims 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 5
- 201000002528 pancreatic cancer Diseases 0.000 claims 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000008177 pharmaceutical agent Substances 0.000 claims 4
- 229910052697 platinum Inorganic materials 0.000 claims 4
- 239000012270 PD-1 inhibitor Substances 0.000 claims 3
- 239000012668 PD-1-inhibitor Substances 0.000 claims 3
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 3
- 230000002411 adverse Effects 0.000 claims 3
- 239000004052 folic acid antagonist Substances 0.000 claims 3
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims 2
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims 2
- 239000012824 ERK inhibitor Substances 0.000 claims 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims 2
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229940121647 egfr inhibitor Drugs 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical group [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical group C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024086236A JP2024112968A (ja) | 2022-06-30 | 2024-05-28 | Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263357227P | 2022-06-30 | 2022-06-30 | |
| US63/357,227 | 2022-06-30 | ||
| US202363486785P | 2023-02-24 | 2023-02-24 | |
| US63/486,785 | 2023-02-24 | ||
| US202363496447P | 2023-04-17 | 2023-04-17 | |
| US63/496,447 | 2023-04-17 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024086236A Division JP2024112968A (ja) | 2022-06-30 | 2024-05-28 | Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024007504A JP2024007504A (ja) | 2024-01-18 |
| JP2024007504A5 true JP2024007504A5 (https=) | 2024-04-05 |
| JP7496917B2 JP7496917B2 (ja) | 2024-06-07 |
Family
ID=87468549
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023108177A Active JP7496917B2 (ja) | 2022-06-30 | 2023-06-30 | Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン |
| JP2024086236A Pending JP2024112968A (ja) | 2022-06-30 | 2024-05-28 | Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024086236A Pending JP2024112968A (ja) | 2022-06-30 | 2024-05-28 | Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240108618A1 (https=) |
| EP (1) | EP4547251A1 (https=) |
| JP (2) | JP7496917B2 (https=) |
| KR (1) | KR20250027777A (https=) |
| CN (1) | CN119907671A (https=) |
| CA (1) | CA3260047A1 (https=) |
| IL (1) | IL317823A (https=) |
| MA (1) | MA71325A (https=) |
| MX (1) | MX2025000105A (https=) |
| WO (1) | WO2024006424A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| ES2929700T3 (es) | 2019-12-11 | 2022-12-01 | Lilly Co Eli | Inhibidores de KRas g12c |
| BR112022022021A2 (pt) * | 2020-04-30 | 2022-12-13 | Genentech Inc | Anticorpos, ácido(s) nucleico(s), vetor, célula hospedeira, processo para produzir um anticorpo, métodos para rastrear um anticorpo, detectar kras-gdp, obter um inibidor, detectar a alquilação de kras, tratar um câncer, rastrear compostos, medir a ligação de uma proteína e medir o engajamento do alvo de um inibidor, kit, chaperona de cristalização, método de cristalização e superfície de biossensor |
| US20230285498A1 (en) * | 2020-08-07 | 2023-09-14 | City Of Hope | Treatments for cancers having kras mutations |
| MX2023003060A (es) * | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| EP4486345A1 (en) * | 2022-03-04 | 2025-01-08 | Eli Lilly and Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
-
2023
- 2023-06-29 EP EP23745331.1A patent/EP4547251A1/en active Pending
- 2023-06-29 KR KR1020257002609A patent/KR20250027777A/ko active Pending
- 2023-06-29 IL IL317823A patent/IL317823A/en unknown
- 2023-06-29 CN CN202380063188.1A patent/CN119907671A/zh active Pending
- 2023-06-29 US US18/344,134 patent/US20240108618A1/en active Pending
- 2023-06-29 WO PCT/US2023/026554 patent/WO2024006424A1/en not_active Ceased
- 2023-06-29 CA CA3260047A patent/CA3260047A1/en active Pending
- 2023-06-29 MA MA71325A patent/MA71325A/fr unknown
- 2023-06-30 JP JP2023108177A patent/JP7496917B2/ja active Active
-
2024
- 2024-05-28 JP JP2024086236A patent/JP2024112968A/ja active Pending
-
2025
- 2025-01-06 MX MX2025000105A patent/MX2025000105A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024007504A5 (https=) | ||
| IL317823A (en) | KRAS G12C inhibitor for cancer treatment | |
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| RU2508110C2 (ru) | КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek | |
| EP2762140B1 (en) | Treatment of solid brain tumours with a rapamycin derivative | |
| KR101434009B1 (ko) | 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물 | |
| JP2022171808A (ja) | リポソームイリノテカン、オキサリプラチン、５－フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 | |
| JP2024133474A5 (https=) | ||
| CN104114168A (zh) | 治疗增殖性疾病的联合疗法(威罗菲尼和mdm2抑制剂) | |
| Curigliano et al. | Alpelisib in combination with everolimus±exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study | |
| JP2020517696A5 (https=) | ||
| Bennouna et al. | Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| CN110198716A (zh) | 癌症治疗 | |
| JP2022544485A (ja) | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 | |
| JPWO2022269525A5 (https=) | ||
| JP2019508476A5 (https=) | ||
| CN115025090A (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| JPWO2023076991A5 (https=) | ||
| WO2023100070A1 (en) | Cdk4 inhibitor for the treatment of cancer | |
| CA3182018A1 (en) | Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor | |
| CN112584834B (zh) | 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 | |
| JPWO2022170060A5 (https=) | ||
| JP2013531064A (ja) | 難治性癌を治療する方法 | |
| Lara et al. | Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations |